Article Text


G137(P) Patent ductus arteriosus of prematurity: to treat or not to treat?
  1. VM Shetthalli,
  2. S Nittur,
  3. A Wong,
  4. O Uzun
  1. Department of Paediatric Cardiology, University Hospital of Wales, Cardiff, UK


Background Incidence of patent ductus arteriosus in neonates is 30–60% depending on the degree of prematurity. Although patent ductus arteriosus is associated with significant morbidity and mortality in preterm infants, there is a wide variation in management of patent ductus arteriosus in preterm infants.

Methods We reviewed of our 22 year experience from 1992 to 2013 in all neonates diagnosed with a haemodynamically significant patent ductus arteriosus at the University Hospital of Wales. Haemodynamically significant patent ductus arteriosus is described as: (1) left atrium/aortic ratio of >1.5, (2) significant left heart volume overloading, (3) bounding femoral pulses, (4) hyperactive precordium and (5) persistent ventilator requirements.

Results A total of 200 cases were eligible. The results are summarised in the Table 1:

Abstract G137(P) Table 1

Pharmacological treatment = Treatment with either Indomethacin or Ibuprofen

Conclusion There were no significant differences in NEC, IVH, CLD or death between treatment and no-treatment group despite the former cases being at lower gestations with lower birth weights. Our result may lend further support towards non-surgical management of patent ductus arteriosus with medication if treatment is not considered to be contraindicated.

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.